London
· Delayed Price · Currency is GBP · Price in GBXScancell Holdings Company Description
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease.
Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer.
It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, melanoma, ovarian, lung, and pancreatic cancers; and Modi-2, which targets homocitrullinated cancer antigens.
In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus.
Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
| Country | United Kingdom |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 61 |
| CEO | Phillip L'Huillier |
Contact Details
Address: Bellhouse Building Oxford, OX4 4GD United Kingdom | |
| Phone | 44 18 6558 2066 |
| Website | scancell.co.uk |
Stock Details
| Ticker Symbol | SCLP |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | May - April |
| Reporting Currency | GBP |
| ISIN Number | GB00B63D3314 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Phillip L'Huillier | Chief Executive Officer |
| Sathijeevan Nirmalananthan | Chief Financial Officer |